Evaxion appoints Dr Helen Tayton-Martin as new Chief Executive Officer

Core Viewpoint - Evaxion A/S has appointed Dr. Helen Tayton-Martin as the new CEO, effective November 24, 2025, marking a significant leadership change for the company as it continues to develop its AI-Immunology™ powered vaccines [1][4]. Company Leadership - Dr. Helen Tayton-Martin holds a Ph.D. in molecular immunology and an MBA from London Business School, with extensive experience in the biotech sector, including co-founding Adaptimmune and overseeing its growth and strategic partnerships [2][9]. - Birgitte Rønø, who served as interim CEO, will return to her role as Chief Scientific Officer, continuing to lead research and development efforts [5][9]. Board Changes - Dr. Tayton-Martin will step down from Evaxion's Board of Directors upon assuming the CEO role, while Jens Bitsch-Norhave will join the Board as an adviser and observer, with plans to seek election as a board member in 2026 [7][8]. Company Strategy and Potential - Dr. Tayton-Martin expressed excitement about joining Evaxion at a pivotal time, highlighting the company's AI-Immunology platform and recent achievements, such as the out-licensing of EVX-B3 to MSD and promising data for EVX-01 presented at ESMO [6][9]. - Evaxion is focused on developing novel immunotherapies for cancer and infectious diseases, leveraging its AI technology to address high unmet medical needs [11].